title: Novel therapies for non-small cell lung cancer.
abstract: Lung cancer is the leading cause of cancer-related death in the United States. Emerging technologies for the treatment of early-stage non-small cell lung cancer are currently focused on less invasive approaches to obtaining local tumor control, including minimally invasive and less radical resections, as well as image-guided ablative therapies. Targeted chemotherapeutic agents represent the newest area of treatment for advanced non-small cell lung cancer. These novel agents capitalize on our increased understanding of the diverse biology of the disease. Each of these advanced modalities works best for only a small subset of the population with lung cancer, and efficacious use is highly dependent on appropriate patient selection.
authors.affiliation: Department of Cardiothoracic Surgery, NYU School of Medicine, 530 1st Ave, Suite 9V, New York, NY 10016, USA. Jessica.donington@nyumc.org
authors.forename: Jessica S
authors.initials: JS
authors.lastname: Donington
authors.forename: Chi Wan
authors.initials: CW
authors.lastname: Koo
authors.forename: Marc S
authors.initials: MS
authors.lastname: Ballas
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D017115:Catheter Ablation / Q000379:methods; D003952:Diagnostic Imaging; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000235:genetics / Q000401:mortality / Q000628:therapy*; D019060:Minimally Invasive Surgical Procedures; D009367:Neoplasm Staging; D011881:Radiotherapy, Computer-Assisted; D020775:Thoracic Surgery, Video-Assisted; D014481:United States / Q000453:epidemiology
chemical_list: D000970:Antineoplastic Agents